House FDA drug reform bill may be more acceptable to patient groups, patient rep indicates.
HOUSE FDA DRUG REFORM BILL POTENTIALLY MORE ACCEPTABLE TO PATIENT GROUPS than the Senate FDA reform legislation, AIDS Action Council representative Gary Rose indicated July 2. At a press conference organized with Public Citizen, representatives of the American Foundation for AIDS Research, AIDS Action Council, National Organization for Rare Disorders and National Council on Aging criticized the recently-filed committee report on Sen. Kassebaum's (R-Kan.) FDA reform proposal (S 1477).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth